Patient Involvement in Outcome Measures for Psoriatic Arthritis
Authors:
- William TillettWTWilliam Tillett
- Mel BrookeMBMel Brooke
- Willemina CampbellWCWillemina Campbell
- Oliver FitzGeraldOFOliver FitzGerald
- Jana JamesJJJana James
- 13 March 2014
- journal article
- review article
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 16 (5) , 418
Abstract
Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis with a varied clinical phenotype. There has been considerable international collaboration over recent years to develop and prioritise appropriate disease domains and outcome measures to capture all aspects of this complex disease. It has been recognised that patient-reported measures and physician assessments are complementary and, when used together, allow an improved reflection of disease burden. Taking this concept one step further, the experience in rheumatoid arthritis has demonstrated benefits of incorporating the patient perspective in the development of outcome measures. We report a systematic review demonstrating (1) that there has been little incorporation of the patient perspective in the development of outcome measures and domains in PsA, (2) the proceedings from the preliminary patient involvement in outcome measures for PsA (PIOMPSA) meetings, and (3) a proposed roadmap for improving patient involvement.Keywords
This publication has 75 references indexed in Scilit:
- The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)Annals of the Rheumatic Diseases, 2013
- Involving patient research partners has a significant impact on outcomes research: a responsive evaluation of the international OMERACT conferencesBMJ Open, 2013
- Evaluation of spinal mobility measurements in predicting axial psoriatic arthritisClinical Rheumatology, 2011
- Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohortArthritis Care & Research, 2010
- Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial dataArthritis Care & Research, 2010
- Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatmentAnnals of the Rheumatic Diseases, 2010
- Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis IndexAnnals of the Rheumatic Diseases, 2009
- Health care utilization in patients with spondyloarthropathiesRheumatology, 2008
- Development and validation of the health assessment questionnaire II: A revised version of the health assessment questionnaireArthritis & Rheumatism, 2004
- A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasisJournal of the American Academy of Dermatology, 2004